Arrowhead Pharmaceuticals reported results from its Phase 2b SHASTA-2 trial at the American College of Cardiology annual meeting.

The trial evaluated plozasiran in patients with severe hypertriglyceridemia.

Patients receiving a 25 mg dose of plozasiran saw a 58% reduction in fasting triglyceride levels after 48 weeks.

In contrast, the placebo group only experienced a 7% reduction in triglyceride levels.

The findings suggest that plozasiran could be a significant advancement in treating severe hypertriglyceridemia.

These results highlight the potential of RNA interference (RNAi) therapeutics in managing lipid-related diseases.